| abstract |
The disclosure relates to a series of novel prostaglandin intermediates, the preparation of which in sequence constitutes a novel process for the manufacture of known diol intermediates, for example 2,3,3a beta ,6a beta -tetrahydro-5 alpha -hydroxy-4 beta -(3-hydroxyoct-1-trans-enyl)-2-oxocyclopenteno[b]furan, from the readily available norbornadiene, said process comprising fewer and more easily operable stages than previously known processes for the manufacture of said diol intermediates. |